Neurocrine Biosciences, Inc. (NBIX) Stake Maintained by Birchview Capital LP
Birchview Capital LP maintained its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,200 shares of the company’s stock at the end of the second quarter. Neurocrine Biosciences makes up about 0.6% of Birchview Capital LP’s investment portfolio, making the stock its 7th largest position. Birchview Capital LP’s holdings in Neurocrine Biosciences were worth $1,159,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the company. Independent Portfolio Consultants Inc. bought a new position in shares of Neurocrine Biosciences during the first quarter worth approximately $106,000. First Mercantile Trust Co. boosted its stake in shares of Neurocrine Biosciences by 22.2% in the first quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock valued at $133,000 after buying an additional 560 shares during the last quarter. ARS Investment Partners LLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter valued at $207,000. Capstone Asset Management Co. purchased a new stake in shares of Neurocrine Biosciences during the first quarter valued at $214,000. Finally, Grandfield & Dodd LLC boosted its stake in shares of Neurocrine Biosciences by 15.2% in the second quarter. Grandfield & Dodd LLC now owns 6,130 shares of the company’s stock valued at $282,000 after buying an additional 810 shares during the last quarter.
Shares of Neurocrine Biosciences, Inc. (NBIX) traded up 5.32% during midday trading on Thursday, hitting $56.66. 243,903 shares of the stock were exchanged. Neurocrine Biosciences, Inc. has a one year low of $37.35 and a one year high of $56.88. The company’s market cap is $5.00 billion. The firm has a 50 day moving average of $50.23 and a 200-day moving average of $47.62.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.01. The company had revenue of $6.34 million during the quarter, compared to analyst estimates of $0.61 million. During the same quarter last year, the firm earned ($0.46) EPS. Equities analysts expect that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current year.
WARNING: This piece was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/31/neurocrine-biosciences-inc-nbix-stake-maintained-by-birchview-capital-lp.html.
Several equities research analysts have recently commented on NBIX shares. Piper Jaffray Companies set a $68.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Thursday, August 24th. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Cowen and Company reiterated an “outperform” rating and issued a $65.00 price target (up from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. BMO Capital Markets raised their price objective on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a research note on Friday, August 4th. Finally, Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $70.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, July 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seventeen have given a buy rating to the company’s stock. Neurocrine Biosciences presently has an average rating of “Buy” and a consensus target price of $68.25.
In related news, insider Haig P. Bozigian sold 22,500 shares of Neurocrine Biosciences stock in a transaction on Friday, August 4th. The stock was sold at an average price of $50.00, for a total value of $1,125,000.00. Following the transaction, the insider now directly owns 154,601 shares in the company, valued at approximately $7,730,050. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dimitri E. Grigoriadis sold 15,354 shares of Neurocrine Biosciences stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $55.00, for a total value of $844,470.00. Following the completion of the transaction, the insider now owns 123,045 shares in the company, valued at $6,767,475. The disclosure for this sale can be found here. Insiders sold a total of 46,588 shares of company stock worth $2,406,170 over the last 90 days. Insiders own 4.80% of the company’s stock.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.